echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Good news for Chinese Parkinson patients! Youshibi neupro (rotigotine patch) approved by China

    Good news for Chinese Parkinson patients! Youshibi neupro (rotigotine patch) approved by China

    • Last Update: 2018-07-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    July 3, 2018 / BIOON / -- Belgian pharmaceutical giant UCB recently announced that it has obtained import drug license (IDL) of neupro (rotigotine patch) from China National Drug Administration This means that neupro has been officially launched in China for the treatment of Parkinson's disease (PD) Click on the video: apply the neupro patch correctly Parkinson's disease (PD) is a chronic, degenerative nervous system disease, with an estimated prevalence of 1.7% in Chinese people aged 65 and over, and about 3 million people are troubled by the disease Neupro is a sustained-release patch that can deliver rotigotine via the skin It is a non ergot selective dopamine receptor agonist, which can produce anti Parkinson effect by activating D3 / D2 / D1 Pharmacological studies show that rotigotine has obvious anti Parkinson effect and neuroprotective effect Neupro can be used as a single drug therapy (for example, not combined with levodopa) or combined with levodopa to treat the symptoms and signs of patients with idiopathic Parkinson's disease in the early stage The drug can be used for the whole course of the disease until the efficacy of levodopa in the late stage decreases or becomes inconsistent and fluctuates Niopro is designed to support and improve the treatment experience of patients with Parkinson's disease The product adopts a unique transdermal patch preparation, which is administered once a day, and can continuously release rotigetine within 24 hours, significantly improving the symptoms and signs of patients with Parkinson's disease Jeff Wren, head of youshibi's neurological patient value unit, said that neupro's listing in China reflects our commitment to provide added value to patients around the world We know that Parkinson's disease has an important impact on the lives of patients and their families, and we also know how important it is to manage symptoms effectively to keep patients independent and maintain their quality of life With the approval of neupro in China, we are happy to bring this drug to millions of Parkinson's patients, and provide them with a convenient treatment plan to help them manage their condition.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.